Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.